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Previous studies revealed the potential significance of circulating adiponectin levels with
respect to the diagnosis and prediction of metabolic syndrome, but uncertainty has
been noted across different cohorts. Systematic evaluation was performed for diagnostic
accuracy and predictivity of adiponectin variation for metabolic syndrome in enrolled
studies including 1,248 and 6,020 subjects, respectively. Adiponectin can identify
metabolic syndrome with moderate accuracy (area under the curve = 0.81, 95% CI:
0.77–0.84). Heterogeneity analysis revealed that an increasing index of insulin resistance
was independently associated with improving the performance of adiponectin upon
metabolic syndrome diagnosis (ratio of diagnostic odds ratio= 3.89, 95%CI: 1.13–13.9).
In addition, reductions in adiponectin were associated with increasing metabolic
syndrome incidence in a linear dose-response manner. The risk of hypoadiponectinemia
with metabolic syndrome was especially increased in men (P < 0.05). Further Mendelian
randomization analysis identified that the amplified risk could be attributed to increased
susceptibility (up to 7%) to insulin resistance compared with women. In conclusion,
adiponectin measurement might have potential benefits in the detection of metabolic
syndrome. Factors that affect insulin resistance should be considered for adjustment in
future assessments.
Keywords: adiponectin, metabolic syndrome, diagnostic accuracy, prediction, meta-analysis
INTRODUCTION
Metabolic syndrome (MetS) is defined as a panel of endocrine disorders, including central
adiposity, dyslipidemia, hyperglycemia and hypertension (Kaur, 2014). Cored by insulin resistance,
MetS (diagnosed using different criteria) is a crucial mediator in promoting the incidence of
non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, cardiovascular disease (CVD) and
subsequent mortality (Ford, 2005; Gami et al., 2007). Given the increasing health burden from
excessive calorie intake and absence of physical inactivity, MetS is a pandemic disease that affects
greater than 25% of the global population and has caused comprehensive concerns worldwide
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(Grundy, 2008, 2016). MetS development involves numerous
cytokines (Matsuzawa, 2006; Rizvi, 2009; Maury and Brichard,
2010), and systematic knowledge of key factors is beneficial for
further mechanistic investigation and disease prevention.
Adiponectin (ADPQ), which is encoded by the AdipoQ
gene located on chromosome 3q27.3, is a 244-amino acid
pleiotropic hormone with a molecular weight of approximately
30 kDa for its basic subunit. ADPQ is exclusively secreted by
adipocytes, and abundant levels in the circulation are eliminated
by liver. ADPQ consists of different multimerizations, including
low molecular weight (LMW) and high molecular weight
(HMW) hexamers. The HMWmultimer is considered the major
active functional component of ADPQ (Robinson et al., 2011).
Previous studies revealed that adiponectin played a causal role
in maintaining energy homeostasis via regulation of glucose
and lipid metabolism. Particularly, adiponectin can alleviate
insulin resistance by stimulating the cellular glucose uptake
and organ/circulating fatty acid oxidation via activation of key
proteins, including adenosine monophosphate-activated protein
kinase (AMPK) and peroxisome proliferator activated receptor
gamma (PPAR-γ) (Yamauchi et al., 2001, 2002; Tschritter et al.,
2003; Kadowaki et al., 2006). ADPQ is an effective biomarker for
the prediction and risk classification of insulin resistance (IR) and
its related complications (Tschritter et al., 2003; Yamamoto et al.,
2004; Hara et al., 2006). Furthermore, pre-clinical studies in mice
demonstrated the therapeutic potential for ADPQ administration
on improving insulin sensitivity. ADPQ is considered an ideal
target for drug development to treat IR-related metabolic
disorders (Yamauchi et al., 2001; Shetty et al., 2009).
MetS involves systemic insulin resistance with a collection
of risk indicators on cardiovascular disease (Roberts et al.,
2013). Genetic studies also identified that hypoadiponectinemia
shared common genetic constitutions with MetS pathogenesis
(Comuzzie et al., 2001; Yang and Chuang, 2006). Hence, the close
relationship between ADPQ andMetS risk is not surprising. Even
in obese children, ADPQ also exhibited a decreasing tendency
in subjects with insulin resistance and potentially influenced
subsequent MetS development (Weiss et al., 2004).
Epidemiology surveys provide clues for mechanistic study
and approaches to estimate its diagnostic potential. Accordingly,
several longitude studies identified that circulating ADPQ might
predict MetS incidence even after adjusting for crucial metabolic
confounders, such as obesity (Seino et al., 2009; Juonala et al.,
2011; Nakashima et al., 2011; Kim et al., 2013a; Hata et al., 2015;
Lindberg et al., 2017). Otherwise, ADPQ was also measured to
evaluate its accuracy upon MetS diagnosis across studies with
populations from different ethnicities and age groups (Ogawa
et al., 2005; Gilardini et al., 2006; Mojiminiyi et al., 2007; Lee
et al., 2008; Boyraz et al., 2013; Patel et al., 2015). However, the
utility of ADPQ as a candidate biomarker in MetS prediction and
risk assessment seems paradoxical across studies with uncertain
hazard extents for potential differences regarding ethnic origin,
gender, samples, comparisons, obesity or other disease status.
To date, previous evidence-based studies only assessed the
impact of ADPQ variation on the development of individual
features, such as hypertension and hyperglycemia (Li et al.,
2009; Kim et al., 2013b). While impact of ADPQ on MetS as
systemic manifestation of metabolic disturbance was not assessed
(Eckel et al., 2005). To fill in this gap, it is worthwhile to
systematically summarize the adiponectin-MetS relationship to
provide comprehensive knowledge to improve the diagnosis and
treatment of MetS.
Therefore, our current study mainly analyzed the following
parameters: (1) accuracy of circulating ADPQ upon MetS
diagnosis; (2) causal impacts of varied blood ADPQ on
MetS development based on published results. Factors causing
heterogeneity were also assessed by subgroup analysis.
METHODS
This study was conducted strictly according to the Preferred
Reporting Items for Systematic Reviews and Meta Analyses
(PRISMA) criteria (Moher et al., 2009). Details of reporting
items are presented in the Supplementary PRISMA Checklist.
The study was divided into two interrelated topics based on the
analysis of ADPQ as a potential biomarker in MetS diagnosis
and prediction. The first goal was to estimate the diagnostic
accuracy of ADPQ as a potential tool for MetS detection (namely,
accuracy analysis). The second goal was to assess the relationship
between blood ADPQ and MetS risk based on longitudinal
studies (namely, risk assessment).
Search Strategy
Three electronic databases, including PubMed (National Library
of Medicine, Bethesda, Maryland, USA), Embase (Elsevier,
Amsterdam, Netherlands) and ISI Web of Science (Thomson
Reuters, London, UK), were searched up to March 1st, 2018 with
the help of an experienced librarian. The criterion for the enrolled
studies was that they should be performed with humans and
published as original full papers without language restriction.
The following subject terms were applied to the literature
search: “adiponectin”; “ADIPOQ”; “ADPQ”; “ACDC”; “GBP-
28”; “apM1”; “Acrp30”; “metabolic syndrome”; “MetS”; “MS”;
“syndrome X” and “insulin resistance syndrome.” More details
about the search strategy in a separate database are presented in
Table S1.
Additionally, relevant papers were searched manually if
omitted in routine retrieval but identified in reference lists of
enrolled studies.
Eligibility Criteria
For accuracy analysis, only studies with content that referred
to the precision of ADPQ measurement upon MetS diagnosis
were considered. In addition, qualified studies should meet the
following criteria: 1. necessary data to construct 2 × 2 table
for MetS by ADPQ test at best cutoff and largest area under
the receiver operating characteristic (AUROC) curves should be
provided or extractable by software; 2. MetS was diagnosed with
pre-defined criteria.
With regard to risk assessment, we only included prospective
studies related to the impact of blood ADPQ onMetS occurrence
that simultaneously met the following criteria: (1) no patients
with MetS at baseline; (2) pre-defined definition for MetS
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diagnosis; (3) hazard ratios based on ADPQ variation were
provided or could be derived from calculations.
All studies that met the inclusion criteria were enrolled
regardless of study population or sample size. If duplicate data
were observed in different studies, we only collected the most
recent dataset with detailed information.
Data Extraction
Two authors (ZL and SQ) independently extracted information
from eligible studies with predesigned unified standardized
reporting forms separated by study topics. If relevant information
was not provided directly in the enrolled study but presented
in attached diagrams, available data would be digitized and
extracted via Plot Digitizer software (downloaded on http://
plotdigitizer.sourceforge.net/).
For accuracy analysis, the following information was
extracted: data source (author, country and publication
year), population characteristics (age, gender, number), study
design, sampling (ADPQ forms, methods and samples for
measurements), definition and prevalence of MetS, and accuracy
of ADPQ on MetS diagnosis (sensitivity, specificity, and
corresponded AUROC).
Similarly, most items in the accuracy analysis were also
included in reported information for risk assessment. However,
data accuracy was replaced by MetS risk based on ADPQ
variations, including comparison, effect size, calculation and
adjusted covariates.
Rescaling of Covariates
The HOMA-IR index was calculated using the following formula
when it was not directly provided in the original study: fasting
insulin (µU/L) × fasting glucose (nmol/L)/22.5 (Matthews
et al., 1985; Whiting et al., 2011). Regarding combinations of
quantitative covariates from different subgroups, the data were
calculated based on number, mean level and related standard
deviation according to pre-defined formulas (Higgins and Green,
2011).
Quality Assessment
Two investigators performed quality assessment for each enrolled
study based on different scoring systems divided by research
topics.
For accuracy analysis, we adopted the QUADAS-2 scale
(Whiting et al., 2011) to evaluate potential heterogeneity and
applicability of enrolled studies. The checklist contained four
items related to subject’s selection: index test, standard reference,
study flow and timing (Supplementary QUADAS-2 checklist).
Risk of bias for each item in individual study was rated as
“low,” “high,” and “unclear” and summarized by proportion.
For risk assessment, we chose the NOS checklist designed for
nonrandomized cohort studies (Stang, 2010; Wells et al., 2016)
to evaluate the potential confounders that caused bias in pooled
results. Accordingly, we modified some items to better adapt this
scale to our quality assessment (Supplementary NOS checklist).
In general, the NOS included nine items from three dimensions,
including cohort selection, comparability, and outcome
assessment. Studies that received a score greater than 6 were
considered high quality.
Data Synthesis and Statistical Analysis
Pooled test performance of ADPQ detection on MetS diagnosis
was evaluated by calculating summary measures of sensitivity
(SEN), specificity (SPE), positive likelihood ratio (PLR), negative
likelihood ratio (NLR), diagnostic odds ratio (DOR) and their
corresponding 95% confidence intervals (CI) within a random-
effect framework based on bivariate original data (true positives
[TP], false positives[FP], false negatives [FN], and true negatives
[TN]) extracted from studies (Reitsma et al., 2005). Negative
predictive value (NPV) and positive predictive value (PPV)
in cohorts with different MetS prevalence were estimated by
pooled SEN and SPE (Altman and Bland, 1994). ROC curves
were plotted using a hierarchical regression model (Rutter
and Gatsonis, 2001) based on paired sensitivity and specificity
from individual studies. Summarized AUROC was calculated
to present the test performance, and synthesized diagnostic
accuracy was classified as low (0.5–0.7), moderate (0.7–0.9), and
high (0.9–1) based on area under curve (AUC) values according
to prior criteria (Swets, 1988). The significance of the threshold
effect was tested by Spearman correlation between logit SEN/1-
SPE (Zamora et al., 2006). The areas under ROC curves across
different cohorts were compared by Z test. Diagnostic accuracy
was estimated in subgroups categorized by participant features
(age, gender), sample size, study design, ADPQ measurement
(cutoff, specimen, methods), and MetS definition/prevalence.
A multi-covariate meta-regression model was implemented to
explore the impact of potential confounders on diagnostic
accuracy based on prior subgroup analysis.
For assessment of predictive validity, we extracted multi-
covariates adjusted, gender-specificOR values and corresponding
95% CIs (if provided) from original studies to evaluate the
risk of hypoadiponectinemia associated with MetS occurrence.
Quantitative variation of ADPQ by dichotomous covariate (i.e.,
gender) was calculated by standardized mean differences (SMD)
and corresponding 95% CI. The overall effect was assessed by
integration of MetS risk compared between groups with highest
and lowest ADPQ levels. Risk extent was transferred by obtaining
the reciprocal of given indicator, i.e., 1/OR as proposed before
(Tierney et al., 2007), if the control was set as the group
with the highest ADPQ values. Cumulative incidence rate of
MetS was calculated by the previously mentioned formulation
(McDermott et al., 2010). The data were combined based on
subject number, mean level and corresponding standard deviance
(SD) using a previously described formula (Higgins and Green,
2011). Furthermore, a dose-response meta-analysis of the risk of
MetS occurrence associated with a 1 mg/L increase in ADPQ was
performed by GLS for trend models (Greenland and Longnecker,
1992; Orsini et al., 2006) based on median ADPQ dose, number
of total participants/MetS cases, risk measures and 95% CI
compared with subjects with baseline ADPQ values. Then,
we assessed the potential non-linearity of the dose-response
relationship between ADPQ and MetS risk using two-step GLST
methods. Specifically, the slope line was estimated in each
individual study using restricted cubic spline functions at four
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fixed knots assigned with 5th, 35th, 65th, and 95th percentiles
of the distribution of the ADPQ level and combined with the
overall average spline using the maximum likelihood method
in a random-effects model (Harre Jr et al., 1988; Desquilbet
and Mariotti, 2010; Orsini et al., 2011). A non-linearity test was
implemented based on the null hypothesis that the coefficient of
combined spline was equal to 0. Median ADPQ dose that was not
directly provided in studies was assigned as the midpoint of the
upper and lower limit value in each specific category. For open
ended data, the median dose was assigned as lower bounds× 1.2
in the highest group or upper bounds × 0.8 in the lowest group
(Berlin et al., 1993).
With regard to the heterogeneity analysis, subgroup
analysis categorized by participant features (age, gender,
ethnicity, BMI, HOMA-IR), sample size, follow-up and disease
definition/prevalence was performed on the pooled dose-
response risk of ADPQ variation with MetS incidence. The
interaction of potential confounders on ADPQ-MetS association
was assessed using a Mendelian randomization approach as
previously described (Smith and Ebrahim, 2004). Sensitivity
analysis was also conducted to assess the reliability of the effect
estimates by re-evaluation of pooled risk on the remaining
results after sequentially omitting each individual study.
Publication bias was estimated and presented by different
methods. For diagnostic accuracy, publication bias was assessed
visually by scatter plot based on log-transformed DOR vs.
the inverse of the square root of effective sample sizes (ESS,
Deek’s funnel plot). And quantitative tests of their associated
asymmetry were assessed using a regression model (Deeks et al.,
2005). For risk assessment, publication bias was detected using
Begg’s correlation and Egger’s asymmetry test and visualized
by Begg’s funnel plot (Begg and Mazumdar, 1994; Egger et al.,
1997). A measure of statistical heterogeneity across individual
studies was quantified using the I2 test. The threshold for low,
moderate and high degree of inconsistency was assigned as 25,
50, and 75%, respectively (Higgins et al., 2003). A random-effect
model was applied to estimate the pooled effects with significant
heterogeneity (I2 > 50%), whereas a fixed-effect model was used
for results with less heterogeneity (I2 < 50%), except for specific
illustrations (DerSimonian and Laird, 1986).
All calculations were performed by Meta-DiSc (version 1.4)
and STATA (Stata/SE 12.0 for Windows, College Station, TX,
USA) software. A two-sided P-value < 0.05 was considered
statistically significant.
RESULTS
This study was performed and reported strictly according to the
statement on Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) (Moher et al., 2009). More details
are presented in the Supplementary PRISMA Checklist and
flow diagram (Figure S1).
Literature Retrieval and Study Selection
The literature search procedure is presented in Figure 1.
In total, 18410 original studies were obtained based on a
predesigned search strategy (Table S1). Unpublished studies were
not considered for inclusion. After removing 5,532 duplicates, 30
studies were selected by reviewing titles and abstracts. Thirteen
studies were identified to fulfill the eligibility criteria and were
included in the final analysis. Among enrolled literature, six
studies (Ogawa et al., 2005; Gilardini et al., 2006; Mojiminiyi
et al., 2007; Lee et al., 2008; Boyraz et al., 2013; Patel et al., 2015)
focused on diagnostic accuracy; five studies (Seino et al., 2009;
Juonala et al., 2011; Nakashima et al., 2011; Kim et al., 2013a;
Lindberg et al., 2017) focused on longitude risk extent; and one
study (Hata et al., 2015) focused both on topics referred above.
Quality Assessment
Assessment of methodological quality with regard to diagnostic
accuracy of ADPQ upon MetS diagnosis was performed based
on the Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) tool. In general, enrolled studies have high quality
for low risk in each item of bias assessment. One study (Patel
et al., 2015) had a high risk of bias for the adoption of predesigned
cut-off values. Another study (Mojiminiyi et al., 2007) exhibited a
high risk of bias for the enrollment of diabetic patients (Table S2).
The quality of each item for all studies based on the QUADAS-2
tool is summarized in Figure S2.
To assess MetS risk based on ADPQ variation, the
modified Newcastle-Ottawa scale (NOS) scale was adopted
for quality assessment (Supplementary NOS Checklist). All
enrolled studies scored ≥6 and were considered to exhibit high
quality regarding reliability and validity (Table S3). With respect
to factors with low evidence quality identified in individual
studies, two studies (Seino et al., 2009; Hata et al., 2015) did
not adjust potential confounders in the risk assessment. Two
studies (Kim et al., 2013a; Hata et al., 2015) had defects regarding
outcome assessment, specifically, a short follow-up duration or
lower response rate.
Characteristics of Enrolled Studies
The features of enrolled studies regarding accuracy test and risk
assessment are described in Tables 1, 2, respectively. One study
(Hata et al., 2015) assessed both accuracy and prediction.
Regarding the validity of ADPQ measurements with respect
to the diagnosis of MetS, greater than 1248 subjects (803 males
and 445 females, with 26.6% MetS prevalence) were included in
the final analysis. Adolescent (mean age range: 11–14 years) and
adult participants with various backgrounds (diabetes mellitus
[DM] or general subjects with ages ranging from 40 to 65 years)
were involved in four and three studies, respectively. Obese
participants were enrolled in most (three in four) adolescent
studies.
The state of insulin resistance was reported or can be
evaluated via calculation in a majority of the studies except
one (Hata et al., 2015). Extremely severe insulin resistance was
noted in adolescents from one US study (Homeostatic Model
Assessment for Insulin Resistance [HOMA-IR] index: 8 and 7.6
for African-Americans and Caucasians, respectively) (Lee et al.,
2008) compared with the remaining studies (ranged between 2.13
and 4.83). Studies were cross-sectional (n = 6) and prospectively
(n = 1) designed. Total ADPQ levels were measured in serum
(n = 6) or plasma (n = 1) and assessed by enzyme-linked
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FIGURE 1 | Flow diagram of selection for qualified studies in meta-analysis. AUROC, area under the receiver operating characteristic; DM, diabetes mellitus; HMW
ADPQ, high-molecular weight adiponectin; MetS, metabolic syndrome; SEN, sensitivity; SPE, specificity.
immunoabsorbent assay (ELISA, n = 4) or radioimmunoassay
(RIA, n = 3). In all adolescent studies, serum was sampled for
ADPQ measurements.
For risk assessment of ADPQ and MetS incidence, six
prospective studies including 6,020 general adults were included
in the final analysis. Qualified participants included 3,412 men
and 2,608 women aged between 31 and 63 years with similar
average body mass index (BMI) of approximately 22.8–24.2
kg/m2. TheHOMA-IR index could not be obtained in two studies
(Hata et al., 2015), and the value was similar among the other
three studies (ranged between 1.16 and 1.56). Four studies with
3,996 participants and corresponding 19,789.79 person-years in
follow-up duration were extracted to assess linearity and dose-
response risks. The MetS incidence differed across individual
studies (6.4–20.5%) with varied in follow-up durations (2.6–
9.4 years). The average MetS incidence rate was 32.5 cases per
1,000 person years in all studies (30.7 for men and 46.0 for
women). All studies measured the total ADPQ value in serum
(n = 4) or plasma (n = 2) samples using ELISA (n = 2) or
RIA (n = 4) methods. Additionally, two studies (Seino et al.,
2009; Nakashima et al., 2011) also tested high-molecular-weight
(HMW) ADPQ, which is considered a more sensitive predictor
in screening MetS progression (Hara et al., 2006). All studies
reported the odds ratio (OR, n = 4), hazard ratio (HR, n = 1) or
both (n = 1) as indicators to estimate the risk measures of MetS
occurrence based on ADPQ variation. Risk trends followed with
varied ADPQ categories in each individual study are presented in
Figure S3.
The MetS definitions for all enrolled studies (n = 12) are
summarized in Table S4. For adults, most studies (6 in 8)
adopted joint interim criteria (Grundy et al., 2005; Alberti
et al., 2009). The remaining two studies used criteria defined by
the National Cholesterol Education Program Adult Treatment
Panel III (NCEP-ATP-III) (Expert Panel on Detection, 2001)
and a Japanese committee (Matsuzawa, 2005). For adolescents,
definitions from the World Health Organization (Organization,
1999) and NCEP criteria for children (Weiss et al., 2004) were
applied in two studies and one study, respectively. One Japanese
study adopted self-defined criteria.
The ADPQ value categorized by MetS status was presented
in studies related to diagnostic accuracy (n = 5) and risk
assessment (n= 4). The average ADPQ levels in eachMetS group
were less than corresponding values from the non-MetS group
(Figure S4). In total, ADPQ values was reduced significantly
in MetS compared to non-MetS subjects, no matter in groups
regarding diagnostic accuracy (8.94 ± 5.84 vs. 10.44 ± 6.33
ug/ml) or risk prediction (9.18± 4.96 vs. 9.88± 5.00 ug/ml, both
P < 0.01).
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Accuracy of ADPQ in MetS Diagnosis
The diagnostic accuracy of the ADPQ assay in MetS diagnosis
was based on ten data clusters extracted from all seven extractable
studies. As shown in Figure 2, the pooled sensitivity and
specificity were 0.78 (95% CI: 0.72–0.83) and 0.68 (95% CI: 0.59–
0.76), respectively. Correspondingly, the pooled PLR, NLR, and
DOR were 2.44 (95% CI: 1.87–3.18), 0.32 (95% CI: 0.25–0.42),
and 7.62 (95% CI: 4.78–12.2), respectively. NPV and PPV were
0.90 and 0.47, respectively, based on average MetS prevalence
(26.6%) in enrolled studies (Table S5). The area under the
hierarchical summarized ROC curve was 0.81 (95%CI: 0.77–0.84,
Figure 3A).
Regarding heterogeneity observed across enrolled studies, the
I2 values for pooled SPE (84.2%), PLR (71.6%), and DOR (45.5%)
were increased compared with SEN (35.7%) and NLR (39.3%).
Different cut-off values across enrolled studies did not influence
the test accuracy for an insignificant threshold effect of ADPQ on
MetS diagnosis (P = 0.841). Subgroup analysis was performed to
investigate the impact of potential confounders on overall effects
(Table 3). For SEN, the heterogeneity was significantly decreased
in studies with adolescents, lower ADPQ cutoff value, and low
MetS prevalence (all I2 < 25%). SEN was significantly increased
in a cohort of DM patients (Lee et al., 2008) using plasma
samples for ADPQ measurement (0.88 vs. 0.75, P = 0.04) with
low heterogeneity (I2 < 25%). With respect to SPE, decreased
heterogeneity was only observed in the male subgroup (I2 = 0%).
Increased SPE was observed in the adolescent cohort (0.76 vs.
0.60, P = 0.01). As a joint effect of SEN and SPE, the summary
DOR (sDOR) was associated with sample selection, DM status,
and HOMA-IR index (P < 0.05). A multi-covariate meta-
regression model found that ADPQ measurements in cohorts
with higher insulin resistance (HOMA-IR > 5) exhibited better
performance in MetS diagnosis (ratio of DOR [rDOR] = 3.89,
95% CI: 1.13–13.39, P < 0.05).
In adolescents, ADPQ had reproducible diagnostic
performance on MetS in obese subjects after excluding a
cohort with an increased HOMA-IR index (Lee et al., 2008)
(sDOR = 6.99, 95%CI: 3.76–12.98, I2 = 23.6%). In adults,
the accuracy of ADPQ in MetS diagnosis was also significant
(sDOR = 4.91, 95%CI: 3.08–7.84), but unstable effects were
FIGURE 2 | Pooled sensitivity and specificity for accuracy of circulating adiponectin upon diagnosis of metabolic syndrome. (A) Pooled sensitivity of ADPQ upon MetS
diagnosis; (B) Pooled specificity of ADPQ upon MetS diagnosis. AA, African American; ADPQ, adiponectin; CA, Caucasian; F, female; M, male; MetS, metabolic
syndrome.
FIGURE 3 | Summary receiver operating characteristic curve for test accuracy of adiponectin upon metabolic syndrome diagnosis. (A) SROC curve for accuracy of
ADPQ upon MetS diagnosis in all cohorts; (B) SROC curve for accuracy of ADPQ upon MetS diagnosis in adult cohorts; (C) SROC curve for accuracy of ADPQ upon
MetS diagnosis in adolescent cohorts. ADPQ, adiponectin; SROC, summary receiver operating characteristic; MetS, metabolic syndrome.
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TABLE 3 | Subgroup analysis for accuracy of adiponectin test on diagnosis of metabolic syndrome.
Sensitivity Specificity Joint effect
N Mean (95%CI) I2(%) P Mean (95%CI) I2(%) P P
AGE
<18 6 0.76(0.68–0.82) 9.1 0.76(0.72–0.80) 66.5
>18 4 0.80(0.73–0.86) 58.4 0.52 0.60(0.55–0.64) 49.0 0.01 0.08
GENDER
Male 4 0.74(0.66–0.81) 25.8 0.62(0.57–0.67) 0
Female 2 0.86(0.76–0.94) 65.5 0.68(0.58–0.76) 93.2
Mixed 4 0.78(0.70–0.85) 0 0.78 0.78(0.73–0.82) 74.5 0.20 0.11
DM COHORT
Yes 2 0.88(0.79–0.94) 15.9 0.51(0.37–0.65) 71.4
No 8 0.75(0.69–0.80) 0 0.04 0.70(0.67–0.73) 82.2 0.17 0.02
BASELINE ADPQ VALUE (ug/ml)
<10 5 0.74(0.66–0.81) 12.6 0.68(0.65–0.72) 85.2
>10 5 0.82(0.75–0.87) 35.2 0.24 0.70(0.64–0.75) 82.8 0.79 0.38
BASELINE HOMA-IR
<5 8 0.77(0.70–0.83) 0.63(0.53–0.73)
>5 2 0.85(0.72–0.94) 0 0.33 0.80(0.74–0.86) 0 0.07 0.03
MEAN BMI
<30 6 0.76(0.70–0.81) 26.8 0.68(0.64–0.71) 79.7
>30 4 0.82(0.74–0.88) 41.7 0.38 0.71(0.65–0.77) 88.0 0.66 0.54
SAMPLE SIZE
<100 5 0.81(0.75–0.87) 35 0.63(0.56–0.69) 77.1
>100 5 0.82(0.76–0.87) 21.2 0.30 0.65(0.59–0.71) 79.3 0.08 0.09
ADPQ CUT-OFF (ug/ml)
<10 5 0.72(0.65–0.79) 0 0.67(0.64–0.71) 81.7
>10 5 0.83(0.77–0.89) 31.1 0.07 0.72(0.66–0.77) 85.2 0.92 0.10
MetS PREVALANCE (%)
<35 6 0.78(0.71–0.84) 0 0.71(0.68–0.74) 85.7
>35 4 0.78(0.71–0.84) 72.8 0.98 0.59(0.51–0.66) 55.9 0.13 0.20
SPECIMEN
Serum 8 0.75(0.69–0.80) 0 0.70(0.67–0.73) 82.2
Plasma 2 0.88(0.79–0.94) 15.9 0.04 0.51(0.37–0.65) 71.4 0.17 0.02
METHODS
ELISA 6 0.80(0.74–0.85) 28.7 0.69(0.64–0.74) 82.7%
RIA 4 0.75(0.66–0.82) 43.7 0.45 0.69(0.65–0.73) 86.2% 0.37 0.42
ADPQ, adiponectin; BMI, body mass index; DM, diabetes mellitus; ELISA, enzyme-linked immunoabsorbent assay; HOMA-IR, homeostasis model assessment of insulin resistance;
MetS, metabolic syndrome; RIA, radioimmuno assay.
noted for mixtures of DM and normal subjects. Inconsistencies
in sensitivity and specificity were reduced after excluding the
cohort with adult DM patients (both I2 = 0%). Compared
with adolescents, significantly reduced AUC of ADPQ for MetS
diagnosis was observed in adult cohorts (0.70 vs. 0.83, P < 0.05,
Figures 3B,C).
Dose-Response Risk Assessment of ADPQ
in Predicting MetS Incidence
As a biomarker for MetS prediction in a longitudinal study,
the pooled OR of incident MetS compared between subjects
with the highest and lowest ADPQ values was 0.29 (95% CI:
0.19–0.40) with low inter-subgroup heterogeneity (I2 = 23.2%,
P = 0.267) based on five data points incorporated from four
studies (Figure 4A).
An approximately 2.0 cases per 1,000 person-years reduction
in MetS risk was associated with a 1 ug/ml increase ADPQ with
moderate inconsistency across individual studies (pooled OR:
0.94, 95% CI: 0.92–0.96; I2 = 73.7%, P = 0.002, Figure 4B).
However, we did not detect non-linearity in the dose-response
relationship between blood ADPQ value and MetS incidence
based on restricted cubic spline models (P = 0.42, Figure 5A).
The ADPQ-MetS association tended to fit linear trend with
significant inter-subgroup heterogeneity (P = 0.009) based on a
random-effects meta-regression model corrected by generalized
least squares (GLS) estimates (P < 0.01). For data exclusively
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FIGURE 4 | Forest plot on association between circulating adiponectin and metabolic syndrome risk assessed in prospective studies. (A) Pooled OR of MetS
compared between groups with highest and lowest ADPQ levels; (B) Pooled OR of MetS followed per 1 ug/ml ADPQ increase. ADPQ, adiponectin; MetS, metabolic
syndrome; OR, odds ratio.
FIGURE 5 | Dose-response relationship between circulating adiponectin levels and metabolic syndrome risk. (A) Evaluation of association between circulating ADPQ
and MetS risk in all cohorts based on restricted cubic splines and generalized least squares dose-response models; (B) Evaluation of association between circulating
ADPQ and MetS risk in male cohorts based on restricted cubic splines and generalized least squares dose-response models. The solid and long-dashed curves
represent instant estimates of the OR and its 95% CI for MetS risk based on the subgroup with the lowest average ADPQ level based on the restricted cubic splines
model. The short-dashed line represents the estimates of the OR for MetS risk based on the subgroup with lowest average ADPQ level using the generalized least
squares model. ADPQ, adiponectin; CI, confidence interval; MetS, metabolic syndrome; OR, odds ratio.
includingmen, there was no evidence of a non-linear relationship
between circulating ADPQ and MetS (P = 0.12, Figure 5B),
but obvious inter-study heterogeneity was not noted (P = 0.19).
Similarly, the linear trend for the ADPQ-MetS association was
also significant in men based on GLS methods in fixed effect
meta-regression models (P < 0.01). An approximately 4.6 cases
per 1,000 person-year reduction inMetS incidence was associated
with a 1 ug/ml increase in ADPQ in male populations (pooled
OR= 0.85, 95% CI: 0.80–0.90).
Potential confounders of the dose-response MetS risk
were investigated by stratification analysis (Table 4). Age,
ethnicity, follow-up duration, measurement (sample/method),
MetS incidence and definition did not cause significant
inconsistencies in final results (P > 0.05). The reduced OR
in male cohorts compared with females partially contributed
to the heterogeneity (0.85 vs. 0.96, P < 0.01). Intriguingly, a
prominent decrease in the dose-response MetS risk was observed
in cohorts with lower baseline ADPQ levels that monotonically
comprised by men. Further Mendelian randomization analysis
revealed the internal differentiation for gender originated from
increased susceptibility of IR (OR = 1.07, 95%CI: 1.04–1.09)
in men independent of its specific reduction in ADPQ values
(SMD = −1.05, 95% CI: −1.12/−0.97 ug/ml). The pooled OR
was significantly reduced in two Japanese cohorts (Seino et al.,
2009; Hata et al., 2015) with lower MetS incidence (P = 0.002).
However, the lower MetS risk might result from the lack of BMI
adjustment in these studies.
Results from sensitivity analysis also identified that the pooled
results exhibited an approximately 3% reduction compared with
the primary overall results after omitting the only female study
by Kim et al. (2013a) (0.91 vs. 0.94, P = 0.011, Figure S5). In
addition, no individual study significantly influenced the pooled
dose-response OR with ADPQ variation (pooled OR range: 0.94–
0.95, all P > 0.05).
Publication Bias
For diagnostic accuracy, the funnel plot exhibited a symmetrical
shape (Figure S6A). The results from asymmetry tests also
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TABLE 4 | Subgroup analysis for risk assessment of adiponectin on metabolic
syndrome incidence.
N OR (95%CI) I2 Pa1 P
b
2
AGE (YEARS)
<45 3 0.91(0.87–0.95) 75.1% 0.018
≥45 3 0.95(0.93–0.97) 77.8% 0.011 0.158
GENDER
Male 3 0.85(0.80–0.90) 17.6% 0.297
Female 1 0.96(0.94–0.98) NA NA
Mix 2 0.95(0.91–0.99) 0% 0.419 <0.01
ETHNICITY
Caucasian 2 0.95(0.91–0.99) 0% 0.419
East Asian 4 0.94(0.92–0.96) 83.5% <0.001 0.660
FOLLOW-UP (YEARS)
<4 3 0.94(0.92–0.96) 87.7% <0.001
>4 3 0.94(0.90–0.98) 28.6% 0.246 0.979
SAMPLE
Serum 5 0.94(0.92–0.96) 78% 0.001
Plasma 1 0.92(0.89–1.07) NA NA 0.360
METHOD
RIA 4 0.94(0.92–0.96) 81.5% 0.001
ELISA 2 0.94(0.86–1.02) 63.4% 0.094 0.954
MeTS INCIDENCE
<15% 2 0.79(0.69–0.89) 0% 0.508
>15% 4 0.95(0.93–0.96) 67.0% 0.028 0.002
MeTS DEFINITION
NCEP-ATP-III 2 0.95(0.91–0.99) 0% 0.419
Modified NCEP-ATP-III 3 0.94(0.92–0.96) 87.1% <0.001
Other definitions 1 0.83(0.67–0.98) NA NA 0.341
BMI ADJUSTMENT
Yes 4 0.95(0.93–0.96) 67.0% 0.028
No 2 0.79(0.69–0.89) 0 0.508 0.002
BASELINE ADPQ VALUE (mg/L)
<9 3 0.85(0.80–0.90) 17.6 0.297
≥9 3 0.96(0.94–0.98) 0 0.663 <0.01
aP1 value represents heterogeneity in subgroups.
bP2 value represents heterogeneity across subgroups.
ADPQ, adiponectin; BMI, body mass index; ELISA, enzyme-linked immunoabsorbent
assay; MetS, metabolic syndrome; NA, not available; NCEP-ATP-III, National Cholesterol
Education Program Adult Treatment Panel III; OR, odds ratio; RIA, radioimmuno assay.
supported insignificant publication bias across individual studies
(P = 0.379). For risk assessment, convincing evidence indicating
significant publication bias across different studies was not
revealed based on Egger and Begg’s test (P = 0.103 and 0.260,
respectively) despite the slight asymmetry observed in the funnel
plot (Figure S6B).
DISCUSSION
To be best of our knowledge, this is the first evidence-based
study to comprehensively analyze the accuracy and predictive
validity of circulating ADPQ in MetS detection. Compared with
normal subjects, all included studies reported lower average
ADPQ values in the corresponding MetS group (Figure S4),
indicating their undoubted close relationship. As a reliable
estimate for adipocyte function, ADPQ was also recommended
to be combined with HbA1c for early diagnosis of DM in
moderate accuracy (AUROC = 0.85) in previous study (Kälsch
et al., 2015). However, the accuracy and predictive validity of
ADPQ as a single indicator for MetS remained debated across
populations with different backgrounds. Based on published
literature, the ADPQ test is able to distinguish MetS patients
from normal subjects with moderate diagnostic accuracy (pooled
AUROC = 0.81, 95% CI: 0.77–0.84). Pubertal development and
metabolic factors (including insulin resistance and obesity) might
contribute to the heterogeneity of its accuracy.
It was noteworthy that stratified analysis revealed an
increased diagnostic value for ADPQ measurement in specific
populations, such as DM patients and obese adolescents. As a key
covariate, HOMA-IR should be considered for adjustment in this
evaluation. With respect to the predictive validity, results from
prospective studies with 6,020 participants revealed a negative
association between adiponectin levels and MetS incidence in a
linear dose-response fashion. Approximately 6 and 15% increases
in MetS incidence were associated with a 1 ug/ml decrease in
ADPQ in the entire cohort and males, respectively, which is
equivalent to 2 and 4.6 fewer cases per 1,000 person years,
respectively. Despite the relative lower ADPQ level, an increased
risk for hypoadiponectinemia with MetS incidence in men could
explain their intrinsic higher susceptibility (approximately 7%)
for MetS occurrence.
Concerning the clear evidence of effects on alleviating insulin
resistance (Yamauchi et al., 2001; Fu et al., 2005), ADPQ serves
as a potentially valid biomarker to detect MetS in population
studies. One study (Mojiminiyi et al., 2007) reported significant
increases in the pooled SEN and DOR (P < 0.05), possibly
due to its distinct sample selection (plasma) and diabetic status
of participants upon subgroup analysis. However, heterogeneity
tends to originate from DM, but not specimen for high
reproducibility and stability of ADPQ as a secretory protein in
both serum and plasma (Pischon et al., 2003; Yu et al., 2011).
ADPQ has a close relationship with insulin resistance even after
adjusting for central adiposity (Weyer et al., 2001). In our study,
confounding effects of the diabetic status of participants on test
accuracy might have originated from an extremely increased
prevalence of insulin resistance (up to 84%) (Bonora et al., 1998)
in patients with type 2 diabetes, which should be noted and
adjusted in future diagnostic tests. A previous study reported an
increased risk of coronary heart disease and related mortality
based on an interaction with diabetes (Isomaa et al., 2001). It
is worthy for risk stratification to distinguish MetS in patients
with a diabetic background, and ADPQ measurements might be
a suitable candidate for superior diagnostic value in this specific
high-risk population. Correspondingly, approximately four-fold
increased accuracy (rDOR = 3.89, 95%CI: 1.1–13.4, P < 0.05)
in cohorts with increased insulin resistance (HOMA-IR > 5)
also supported this hypothesis regarding insulin resistance as
a potential confounder. The influence of insulin resistance on
diagnostic value should be noted and adjusted in further clinical
practice.
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ADPQ is closely correlated with MetS in adolescents based
on a common influence via the interaction between puberty
and adiposity (Weiss et al., 2004; Punthakee et al., 2006). This
relationship was also significant in non-obese subjects (Weyer
et al., 2001; Abbasi et al., 2004). Consistently, we observed
hierarchical variation in the diagnostic performance of ADPQ
in MetS diagnosis in adults. ADPQ tests for MetS diagnosis
appear to be more accurate in adolescents compared with adults
based on increased false negative rates at the expense of a slight
reduction in true positive rates (Table 3). The efficiency of ADPQ
for MetS diagnosis was also noted in a cohort with a mixture of
normal weight subjects (Lee et al., 2008), indicating its potential
diagnostic value in distinguishing MetS in subjects across the
entire BMI profile. In our study, we observed satisfactory and
reproducible diagnostic values for ADPQ in MetS diagnosis in
adolescent cohorts as evidenced by an increased AUC (0.80,
95% CI: 0.76–0.83). However, increased sDOR in the cohort
with an increased HOMA-IR index (9.98 vs. 6.99, P < 0.05)
indicates that key factors, such as insulin resistance, should be
adjusted. For adults, the efficiency of the ADPQ test upon MetS
diagnosis seems inferior for lower AUROC values (0.70, 95% CI:
0.66–0.74). The lower diagnostic accuracy might be attributed
to the enrollment of normal subjects with a low risk of insulin
resistance. Subgroup analysis cannot be performed due to high
inconsistency and the lack of a description of insulin resistance
in current adult cohorts. More studies in adults with complete
baseline features (especially for covariates referred to insulin
resistance) are required for better risk stratification using ADPQ
in MetS diagnosis.
Prior studies found that modulation of ADPQ level and the
susceptibility of insulin resistance might share a common genetic
basis located in the human 3q27 locus (Vasseur et al., 2003; Yang
and Chuang, 2006). Accordingly, key variations of the APM1
gene that encodes ADPQ protein were associated with MetS
prevalence (Gao et al., 2013; Yuan et al., 2016). However, the
causative role of ADPQ levels as an overall phenotype based on
a gene-environmental interaction upon MetS occurrence has not
been systematically reviewed to date. After pooling the published
data, we observed a consistent and linear increase in MetS
occurrence in subjects with hypoadiponectinemia. Significant
heterogeneity was observed regarding the strength of this
association (I2= 73.7%, Figure 5). Stratification analysis revealed
that gender might confound this causality (Figure 5, Figure S5,
Table 4). Men seem more sensitive to insulin resistance, with
approximately 2.3-fold increasedMetS morbidity compared with
entire cohorts in the same reduction in ADPQ levels.
Androgens modulate the ADPQ level by inhibiting its
secretion from adipocytes to the circulation, and testosterone-
related hypoadiponectinemia might contribute to specific severe
insulin resistance in men (Nishizawa et al., 2002; Xu et al., 2005;
Kadowaki et al., 2006). However, uncertainty still exists regarding
whether the causal effects of this gender-specific correlation are
based on hypoadiponectinemia in men or sexual dimorphism
per se. Based on Mendelian randomization analysis, we observed
inherently increased susceptibility of MetS (approximately 7%)
in men independent of its lower baseline ADPQ level compared
with women (SMD: −1.05 ug/ml). Therefore, significant lower
OR ofMetS incidence associated with ADPQ increased in cohorts
with lower ADPQ levels at baseline (<10 ug/ml, Table 4) might
be better explained as concomitant hypoadiponectinemia with
sexual dimorphism. Gender differentiation as a determinant of
ADPQ-MetS causality should be taken into account in future
longitudinal studies. Considering its potential therapeutic value
(Montecucco and Mach, 2009), male cohorts might experience
more benefits by improving ADPQ function and secretion and
thus preventing MetS.
Centered on insulin resistance, a series of evidence-based
studies revealed appreciable variation in ADPQ levels in patients
with metabolic disorders. The pooled risks for diabetes and
hypertension were approximately 0.72 and 0.94, respectively,
with a 1 log transformed/normal unit increase in ADPQ
(Li et al., 2009; Kim et al., 2013b). Even in patients with
nonalcoholic steatohepatitis (NASH) as a hepatic manifestation
of insulin resistance, the ADPQ value was significantly decreased
(by approximately 2.6 mg/L) compared with normal subjects
(Polyzos et al., 2011). The lower circulating ADPQ level was
observed followed with increased NAFLD activity score (NAS)
and histological severity (Wree et al., 2014). However, evidence is
lacking for pooled effects of hypoadiponectinemia on MetS as a
systemic presentation of insulin resistance (Eckel et al., 2005), key
mediator and precursor of severe clinical complications (Wilson
et al., 2005). Without any exception, lower ADPQ values in MetS
patients were observed compared with non-MetS counterparts
in each individual study (Figure S4), indicating the undoubted
causality between ADPQ and MetS occurrence. Furthermore, we
identified the superiority of the ADPQ test on MetS screening
in high-risk populations with insulin resistance or adiposity.
In addition, the predictive value was significantly affected by
male-specific susceptibility to insulin resistance. These findings
might be helpful to extend the utility of this biomarker for MetS
prevention in further clinical practice.
Currently, ADPQ is considered as crucial adipocytokine
in MetS development (Okamoto et al., 2006). Close
hypoadiponectinemia–MetS association indicates impaired
adipocyte function might significantly influence systemic
insulin resistance (Stern et al., 2007; Klöting and Blüher,
2014). Revese effect of ADPQ on insulin resistance in animal
and epidemiological studies (Yamauchi et al., 2001; Kim
et al., 2015). was also indicative of its clinical implication and
potential therapeutic value on MetS. Hence, ADPQ targeted
pharmacologic intervention (e.g., recombinant adiponectin,
statins, PPARγ agonist, endocannabinoid receptor antagonist
et al.) and lifestyle modifications might (like exercise) have
benefits on improvement of IR even CVD protection (Shetty
et al., 2009; Wang et al., 2015). Consistent with previous
studies, our results confirmed the closely negative dose-response
relationship between ADPQ and MetS development. ADPQ
might be a valuable target for MetS treatment, and extra benefits
might be observed in high-risk subgroups like males or DM
patients. Further clinical intervention studies are worthy to be
performed to validate this viewpoint.
Our study identified ADPQ as a biomarker on detection
of MetS and provided evidence about its causative role on
the development of MetS. The contribution of ADPQ on the
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progression and occurrence of MetS can be studied through the
use of systems biology tools (Bosley et al., 2017; Mardinoglu
et al., 2018) where biological networks have been used in the
analysis and integration of different omics data (Lee et al.,
2017; Mardinoglu et al., 2017a; Uhlen et al., 2017). Recently,
the mechanistic explanation in increased plasma mannose levels
have been revealed through the use of biological networks (Lee
et al., 2016) and it has been validated in large prospective
cohorts (Mardinoglu et al., 2017b). Similar approaches can be
also employed for revealing the mechanistic role of ADPQ on
MetS development.
Certain limitations in our study should be noted. First,
considering the gender differences, sex-specific diagnostic and
predictive validity of ADPQ for MetS should be discussed
separately. However, the dose-response OR cannot be pooled
given the limited number of prospective studies in women (only
one from a Korean population, Kim et al., 2013a). Second,
potential bias might result from uncontrolled methodological
quality in some studies. Third, ADPQ-related MetS risk might
be overestimated for unadjusted OR by BMI and HOMA-
IR. Heterogeneity caused by insulin resistance cannot be
evaluated in the subgroup analysis given that the HOMA
index was not provided in some original data (Hata et al.,
2015; Lindberg et al., 2017). Fourth, although considered the
active multimer of adiponectin with more relevance to protect
against insulin resistance (Oh et al., 2007), the impact of high-
molecular-weight ADPQ on MetS diagnosis and prediction
cannot be pooled and compared with total ADPQ in less
eligible publications (Seino et al., 2009; Nakashima et al.,
2011). Fifth, differences in MetS definitions in cohorts with
specific ethnicities and ages are noted across individual studies
(Table S4). These differences might also cause inconsistency.
However, insignificant heterogeneity was observed in subgroup
analyses (Tables 3, 4).
In conclusion, our study revealed that circulating ADPQ
might serve as an available diagnostic biomarker to identify
MetS subjects, especially in high-risk populations with insulin
resistance. Hypoadiponectinemia predicts increases in MetS
incidence in a linear dose-response fashion, and gender should
be taken into consideration in this evaluation. ADPQ might be
an available target on MetS therapy, but the effects might be
differentiated by patient feature.
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